Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.

Zachary J WalkerBeau M IdlerLorraine N DavisBrett M StevensMichael J VanWyngarden Denis OhlstromShelby C BearrowsAndrew HammesClayton A Smith Craig T JordanTomer M MarkPeter A ForsbergDaniel W Sherbenou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Overall, protein translation inhibitors represent a potential new drug class for myeloma treatment and provide a rationale for conducting clinical trials with omacetaxine alone and in combination with IMiDs for patients with relapsed/refractory multiple myeloma.

Keyphrases

multiple myeloma
clinical trial
protein protein
amino acid
binding protein
emergency department
acute lymphoblastic leukemia
randomized controlled trial
stem cells
risk assessment
study protocol
phase ii
smoking cessation
drug induced